Hepatic Safety of Eviplera(R) in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort." hEPAtic Study.

Trial Profile

Hepatic Safety of Eviplera(R) in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort." hEPAtic Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms hEPAtic Study
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Apr 2015 Planned End Date changed from 1 Dec 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top